Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 13/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31033209 | 1.00 | KLKB1 (0.56) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL23769155 | 0.91 | ALDH1A1 (0.50) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL23469694 | 0.91 | KLKB1 (0.59) | KLKB1BTK | |
| SCHEMBL23769187 | 0.90 | ALDH1A1 (0.52) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL23769282 | 0.90 | ALDH1A1 (0.49) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL23753965 | 0.90 | ALDH1A1 (0.52) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL30027310 | 0.90 | ALDH1A1 (0.52) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL23754188 | 0.89 | ALDH1A1 (0.48) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL23768900 | 0.89 | ALDH1A1 (0.48) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL23769260 | 0.89 | ALDH1A1 (0.48) | KLKB1ALDH1A1LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837252-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-12-10 | — | — | EP | disclosed |
| CN-113039181-B | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-110546146-B | Heteroaryl carboxamide derivatives as plasma kallikrein inhibitors | 勃林格殷格翰国际有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-3612523-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-09 | — | — | EP | disclosed |
| EP-3612523-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-09 | — | — | EP | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| WO-2020035540-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-20 | — | — | WO | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20180305339-A1 | Heteroarylcarboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305339-A1 | Heteroarylcarboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885ALDH1A1 1715/4885LMNA 1489/4885 |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885ALDH1A1 1415/4885LMNA 1430/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885ALDH1A1 1415/4885LMNA 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.